

search

Sub

news news archive



Cellnovo, the leading innovator in mobile diabetes management, announced today that the Company has received the BIOVISION Investment Conference 2014 Award in the medical technology category. The award was presented June 6 at the BIOVISION Investor Conference in Lyon, France.

Introduced in 2013, this conference is a high-level investor event that connects industrial partners and financial investors with the best medical technology, biotechnology, and e-health start-up and mid-size companies. The most promising companies in each category are awarded based upon key criteria such as societal benefit, market attractiveness, innovative approach, competitive position, team structure and attractiveness for investment.

The Cellnovo system is an innovative mobile diabetes management solution that includes a wireless micropump (patch-pump), built-in activity tracker and a cellular enabled touchscreen handset with an integrated blood glucose meter. The proprietary software provides intuitive operation plus connectivity to the cloud for real-time tracking, and the online data management system displays real-time clinical information to healthcare professionals. It is the first system of its kind that allows people with diabetes to enjoy a full lifestyle while closely monitoring blood glucose levels, insulin use, activity and diet.

"We are delighted that BIOVISION has recognized the innovation and business attractiveness of the Cellnovo insulin patch pump and mobile diabetes system," said Eric Beard, executive chairman. "The design and thoughtful integration of our system offers the potential to restore ease of use to people with diabetes by providing freedom from the burdensome procedures of traditional diabetes management."

Cellnovo also received the MediWales Industry Innovation Award in December, 2013.